Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.
Case Based Panel Discussion - Choosing Between Targeted Therapy and Immunotherapy in a Patient with an EGFR Mutation and High PDL-1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss a frail patient with metastatic squamous NSCLC with low tumor PD-L1 expression, and the best treatment approach for this patient.
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss treating a patient with rapidly progressing lung adenocarcinoma and high tumor PD-L1 expression.
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), presents Molecular Diagnostic Testing and Next Generation Sequencing in Lung Cancer webinar series.
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
- 1 of 36
- View More
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are...
New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It's a Poor Choice for Initial Treatment
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce James Stevenson, MD.
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Imprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC isn't Ready for Prime Time
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
- 1 of 207
- View More
Mother-in-Law was diagnosed with NSCLC and after a blood biopsy, doctor is recommending Osimertinib. I tried searching on the main page, but it wasn'...
Wondering if anyone has info on compatibility of berberine with Tarceva. I called Genentech but they didn’t know. I am taking it because it has...
Well, here we are, barring any last minute complications my wife should start the TAK-788 trial next week. She has already had her main blood work...
This seems to be an option for everyone with brain metastases (inform your doctor as it is quite new) ) Here are links to research done in Spain in...
My mum (73years,IVstage,small meta in lymph nodes,EGFR+,exon18,G719X), was for 21 months on 1st line Afatinib (first 40% reduction, last three months...
- 1 of 4
- View More